These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1390219)

  • 1. All-trans retinoic acid improves erythropoiesis in myelodysplastic syndromes: a case report.
    Visani G; Cenacchi A; Tosi P; Finelli C; Fogli M; Gamberi B; Martinelli G; Tura S
    Br J Haematol; 1992 Jul; 81(3):444-6. PubMed ID: 1390219
    [No Abstract]   [Full Text] [Related]  

  • 2. All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome.
    Kurzrock R; Estey E; Talpaz M
    J Clin Oncol; 1993 Aug; 11(8):1489-95. PubMed ID: 8336187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study.
    Giagounidis AA; Haase S; Germing U; Schlegelberger B; Wilkens L; Büsche G; Kreipe HH; Wysk J; Grips KH; Grabenhorst U; Rothmann F; Lübbert M; Ganser A; Aivado M; Heinsch M; Aul C
    Ann Hematol; 2005 Jun; 84(6):389-94. PubMed ID: 15785949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 13-cis-retinoic acid in myelodysplastic syndromes.
    Greenberg BR; Buzaid AC; Meyskens FL
    J Clin Oncol; 1986 Aug; 4(8):1282. PubMed ID: 3525772
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase I-II study of 13-cis-retinoic acid in myelodysplastic syndrome.
    Greenberg BR; Durie BG; Barnett TC; Meyskens FL
    Cancer Treat Rep; 1985 Dec; 69(12):1369-74. PubMed ID: 3865701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [All-trans-retinoic acid in the differential therapy of proliferative hemocytic diseases. I. Properties of biological retinoids].
    Skotnicki AB; Sledziowski P; Sacha T; Jurczak W
    Przegl Lek; 1995; 52(1):31-4. PubMed ID: 7784610
    [No Abstract]   [Full Text] [Related]  

  • 7. [All-trans-retinoic acid in differentiation therapy of hemo-cytopathic proliferative diseases. II. Retinoids in clinical practice].
    Skotnicki AB; Sledziowski P; Sacha T; Jurczak W
    Przegl Lek; 1995; 52(4):145-6. PubMed ID: 7638362
    [No Abstract]   [Full Text] [Related]  

  • 8. Differentiation therapy of myelodysplastic syndromes with retinoic acid.
    Ohno R
    Leuk Lymphoma; 1994 Aug; 14(5-6):401-9. PubMed ID: 7812199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases.
    Itzykson R; Ayari S; Vassilief D; Berger E; Slama B; Vey N; Suarez F; Beyne-Rauzy O; Guerci A; Cheze S; Thomas X; Stamatoullas A; Gardembas M; Bauduer F; Kolb A; Chaury MC; Legros L; Damaj G; Chermat F; Dreyfus F; Fenaux P; Ades L;
    Leukemia; 2009 Apr; 23(4):673-8. PubMed ID: 19151787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome.
    Clark RE; Jacobs A; Lush CJ; Smith SA
    Lancet; 1987 Apr; 1(8536):763-5. PubMed ID: 2882180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anemia in cancer: update on studies of erythropoiesis-stimulating agents.
    Burstein HJ
    J Support Oncol; 2007 Apr; 5(4 Suppl 2):5-26. PubMed ID: 17550053
    [No Abstract]   [Full Text] [Related]  

  • 12. 13-cis-Retinoic acid treatment in patients with myelodysplastic syndrome.
    Leoni F; Ciolli S; Longo G; Messori A; Ferrini PR
    Acta Haematol; 1988; 80(1):8-12. PubMed ID: 3135696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The myelodysplastic syndromes.
    Jacobs A
    Br Med J (Clin Res Ed); 1987 Aug; 295(6597):553-4. PubMed ID: 3117223
    [No Abstract]   [Full Text] [Related]  

  • 14. Myelodysplastic syndrome treatment with danazol and cis-retinoic acid.
    Letendre L; Levitt R; Pierre RV; Schroeder G; Krook JA; Mailliard JE; Morton RF; Tschetter LK
    Am J Hematol; 1995 Apr; 48(4):233-6. PubMed ID: 7717370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
    Guan M; Chen SC; Ge CW
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All-trans retinoic acid in the treatment of myelodysplastic syndromes.
    Visani G; Tosi P; Manfroi S; Ottaviani E; Finelli C; Cenacchi A; Bendandi M; Tura S
    Leuk Lymphoma; 1995 Oct; 19(3-4):277-80. PubMed ID: 8535219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplasia and apoptosis: new insights into ineffective erythropoiesis.
    van de Loosdrecht AA; Vellenga E
    Med Oncol; 2000 Feb; 17(1):16-21. PubMed ID: 10713655
    [No Abstract]   [Full Text] [Related]  

  • 18. Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders.
    Koeffler HP; Heitjan D; Mertelsmann R; Kolitz JE; Schulman P; Itri L; Gunter P; Besa E
    Blood; 1988 Mar; 71(3):703-8. PubMed ID: 3278754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of myelodysplastic syndromes with exogenous erythropoietin: a new therapeutic paradigm.
    Mundle SD; Raza A
    Leukemia; 2006 Sep; 20(9):1481-3. PubMed ID: 16775614
    [No Abstract]   [Full Text] [Related]  

  • 20. Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?
    Tsang E; Leitch HA
    Ann Hematol; 2016 Jan; 95(1):73-78. PubMed ID: 26453076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.